

## Special Issue

# Liquid Biopsy: Current Status and New Challenges

### Message from the Guest Editors

Liquid biopsy is a critical strategic main in precision medicine. Its use allows us to monitor the patient's evolution in real-time. The most crucial role of the LBs is their use as prognostic and predictive markers in different types of tumors. LBs have been accepted as prognostic and predictive markers in numerous solid tumors. Therefore, their use in clinical routine has promoted the need to improve the methodologies for analyzing these markers. However most LBs show a common characteristic, "minimal biological amounts" to work, whether we are talking about CTCs, ctDNA, or tumor educated platelets, which make their use difficult. New methodologies applied to analyze LBs have emerged to solve these limitations. Both allow us to obtain accurate results using minimal samples. More importantly, these advances promote the use of the LBs in other fields beyond metastatic cancer and cancer. The detection of minimal residual disease to predict the risk of relapse in solid tumors is one of the main challenges of using LB. Also, LBs are now open to their use as diagnostic markers in those non-tumoral diseases associated with cancer risk and in cancer interception.

---

### Guest Editors

Dr. María Jose Serrano

1. Medical and Radiotherapeutic Unit, University Hospital Virgen de las Nieves, Avenida de la Ilustración, 114-18016 Granada, Spain
2. Liquid Biopsy and Cancer Interception Group, GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain

Dr. Carmen Garrido Navas

GENyO Centre, Granada, Spain

Dr. Valeria C. Denninghoff

Fundación Pública Progreso y Salud (FPS). Department of General Surgery, Hospital University Virgen del Rocío/CSIC/ University of Seville/Institute of Biomedicine of Seville (IBiS), Seville, Spain

---

### Deadline for manuscript submissions

closed (31 August 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/106294](https://mdpi.com/si/106294)

*Cancers*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/cancers)

[cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)